Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 77

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

Summary

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 12 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Infectious Disease and Undisclosed which include indications Medulloblastoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Peritoneal Cancer, Aspergillosis, Blastomycosis, Cirrhosis, Colon Cancer, Esophageal Cancer, Glioblastoma Multiforme (GBM), Histoplasmosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)

- The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects

- The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Smoothened Homolog (Protein Gx or SMO) - Overview
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
BeiGene Ltd
Genentech Inc
Ignyta Inc
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
Pfizer Inc
Sun Pharma Advanced Research Company Ltd
Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
glasdegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Smoothened Homolog for Medulloblastoma and Colon Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target SMO and HDAC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smoothened Homolog (Protein Gx or SMO) - Dormant Products
Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
Featured News & Press Releases
Jun 27, 2018: U.S. FDA Grants Priority Review for Pfizer's New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
May 21, 2018: HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
May 14, 2018: HedgePath Pharmaceuticals Announces Expanded Patent Coverage
May 02, 2018: Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule
Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency
Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome
Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
Sep 20, 2017: Sun Pharma Odomzo New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma
Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas
Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission
May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Nov 28, 2016: Curis Announces Full Approval of Roche's Erivedge® in the European Union
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by BeiGene Ltd, H2 2018
Pipeline by Genentech Inc, H2 2018
Pipeline by Ignyta Inc, H2 2018
Pipeline by IMPACT Therapeutics Inc, H2 2018
Pipeline by Mayne Pharma Group Ltd, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Dormant Products, H2 2018 (Contd..2), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • Global HPV Therapeutic Vaccines Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 109
    Human papilloma virus (HPV) vaccines are used to protect against HPV infections. Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. Scope of the Report: This report focuses on the ......
  • Global Human Chorionic Gonadotropin (HCG) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 117
    Human chorionic gonadotropin (HCG) is a female hormone produced by the placenta after implantation of the egg, which is why it can be detected in a few pregnancy tests. In addition, it can be extracted from the urine of pregnant women or produced from cultures of genetically modified cells using recombinant DNA technology. Scope of the Report: This report focuses on the Human Chorionic Gonadotropin (HCG) in global market, especially in North America, Europe and Asi......
  • Global Imatinib Drug Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 120
    Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases. Scope of the Report: This report focuses on the Imatinib Drug in global market, especially in North America, Europe and A......
  • 2018-2023 Global Novel Drug Delivery Systems Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 184
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Novel Drug Delivery Systems market for 2018-2023. Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a......
  • 2018-2023 Global Non-Radioactive Nucleic Acid Labeling Product Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Non-Radioactive Nucleic Acid Labeling Product market for 2018-2023. In recent years, non-radioactive nucleic acid labeling and detection methodologies have become available in response to a desire by researchers and their institutions to move away from the use of radioisotopes. Advancements made in the areas of chemiluminescence and fluorescence have allowe......
  • 2018-2023 Global mRNA Vaccines & Therapeutics Consumption Market Report
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 136
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global mRNA Vaccines & Therapeutics market for 2018-2023. mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensu......
  • 2018-2023 Global Compounding Pharmacy Market Report (Status and Outlook)
    Published: 18-Sep-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Compounding Pharmacy market for 2018-2023. The traditional role of compounding pharmacies is to make drugs prescribed by doctors for specific patients with needs that can't be met by commercially available drugs. For example: A young child may need a small, liquid dose of a drug made only in adult-dosage tablets. A person may be allergic to o......
  • Global Japanese Encephalitis ( JE) Vaccine Market Insights, Forecast to 2025
    Published: 18-Sep-2018        Price: US 3900 Onwards        Pages: 110
    This report studies the global market size of Japanese Encephalitis (JE) Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Japanese Encephalitis (JE) Vaccine in these regions. This research report categorizes the global Japanese Encephalitis (JE) Vaccine market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share,......
  • Global Hematology Treatment Market Insights, Forecast to 2025
    Published: 18-Sep-2018        Price: US 3900 Onwards        Pages: 119
    This report studies the global market size of Hematology Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hematology Treatment in these regions. This research report categorizes the global Hematology Treatment market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market driver......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs